These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23229855)

  • 21. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
    Soudry-Kochavi L; Naraykin N; Nassar T; Benita S
    J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers.
    Vlasakakis G; Johnson SL; Lin J; Yao X; Gruenloh CJ; Chism JP; Nunez DJ
    Adv Ther; 2015 Jul; 32(7):650-61. PubMed ID: 26160357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation.
    Chen C; Zheng H; Xu J; Shi X; Li F; Wang X
    Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures.
    Mack CM; Moore CX; Jodka CM; Bhavsar S; Wilson JK; Hoyt JA; Roan JL; Vu C; Laugero KD; Parkes DG; Young AA
    Int J Obes (Lond); 2006 Sep; 30(9):1332-40. PubMed ID: 16534527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
    Liu B; Dong Q; Wang M; Shi L; Wu Y; Yu X; Shi Y; Shan Y; Jiang C; Zhang X; Gu T; Chen Y; Kong W
    Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1474-9. PubMed ID: 21048339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice.
    Iwasaki S; Hamada T; Chisaki I; Andou T; Sano N; Furuta A; Amano N
    J Pharmacol Exp Ther; 2017 Sep; 362(3):441-449. PubMed ID: 28698254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
    Chen C; Zhu X; Dou Y; Xu J; Zhang J; Fan T; Du J; Liu K; Deng Y; Zhao L; Huang Y
    J Biomed Nanotechnol; 2015 May; 11(5):865-76. PubMed ID: 26349398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
    Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models.
    Eldor R; Kidron M; Greenberg-Shushlav Y; Arbit E
    J Diabetes Sci Technol; 2010 Nov; 4(6):1516-23. PubMed ID: 21129350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.
    Xuan J; Lin Y; Huang J; Yuan F; Li X; Lu Y; Zhang H; Liu J; Sun Z; Zou H; Chen Y; Gao J; Zhong Y
    Peptides; 2013 Aug; 46():172-9. PubMed ID: 23770254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats.
    Gilor C; Graves TK; Gilor S; Ridge TK; Rick M
    Domest Anim Endocrinol; 2011 Jul; 41(1):42-9. PubMed ID: 21645806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients ≥ 75 years of age with Type 2 diabetes.
    Linnebjerg H; Kothare PA; Seger M; Wolka AM; Mitchell MI
    Int J Clin Pharmacol Ther; 2011 Feb; 49(2):99-108. PubMed ID: 21255526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys.
    Ai G; Chen Z; Shan C; Che J; Hou Y; Cheng Y
    Int J Pharm; 2008 Apr; 353(1-2):56-64. PubMed ID: 18180118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.
    Ellero C; Han J; Bhavsar S; Cirincione BB; Deyoung MB; Gray AL; Yushmanova I; Anderson PW
    Diabet Med; 2010 Oct; 27(10):1168-73. PubMed ID: 20854385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203).
    Kim J; Kim TH; Choi J; Nam K; Shin BS; Shin S
    Biomed Pharmacother; 2023 Nov; 167():115441. PubMed ID: 37696082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations.
    Lave T; Levet-Trafit B; Schmitt-Hoffmann AH; Morgenroth B; Richter W; Chou RC
    J Pharm Sci; 1995 Nov; 84(11):1285-90. PubMed ID: 8587044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.